FinBoss.io
CSEN
  • Home
  • Crypto prices
  • Bitcoin on-chain
  • US macro
  • US stocks
  • Guides
  • How we make money
FinBoss.io
Home
Crypto prices
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Guides
How we make money
CSEN
Home
Stocks
Resmed Inc
RM

Resmed Inc

RMDHealth care

Stock · Data from SEC EDGAR 13F · Held by 10 of 87 tracked investors

$252.86
▼ 0.08%
Famous investorshold 10buying 0selling 0
Price (USD)
$252.86
Market cap
$35.6B
P/E ratio
24.2
Tracked investors holding
10 of 87
Next earnings
–

Resmed Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
85out of 100
  • Valuation60
  • Growth72
  • Profitability91
  • Quality89
  • Debt100
  • Stability98
In its favour
  • ✓Out of 100 USD of revenue, 27 USD is left as net profit.
  • ✓It earns 24 USD a year on every 100 USD of invested capital (ROE).
  • ✓It has more cash than debt.
  • ✓Revenue grew 10.2% a year over 3 years.
What to watch
  • Nothing notable from the statements.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Reasonably priced

For 1 USD of annual earnings you pay 24.2 USD. Based on next year's estimates 19.1 USD.

P/E
24.2×
P/S
6.3×
EV/EBITDA
17.1×

Is the company growing?

Growing
22
23
24
25
26

Revenue over 3 years grew 10.2% a year. Last year 8.6%.

Does it make money?

Excellent

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

7D
+5.81%
1M
+13.96%
3M
+29.49%
YTD
+3.29%
1Y
-2.56%
3Y
+87.79%
5Y
-3.82%
Forward P/E
19.1
Dividend yield
1.04%
52-week low
$180.27
52-week high
$277.67

Chart RMD

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

10
FR
François Rochon
Giverny Capital
2.54%$75,548,155▲ +68.5%
CA
Cliff Asness
AQR Capital Management
0.06%$177,143,337▲ +160.3%
RD
Ray Dalio
Bridgewater Associates
0.05%$13,131,209▲ +71.7%
Čn
Česká národní banka
Česká národní banka
0.05%$9,163,932unchanged
JG
Joel Greenblatt
Gotham Asset Management
0.04%$16,141,521▼ -14.4%
Šn
Švýcarská národní banka
Swiss National Bank
0.04%$80,072,294▼ -4.1%
KG
Ken Griffin
Citadel Advisors
0.01%$99,054,386▲ +53%
IE
Israel Englander
Millennium Management
0.01%$39,897,977▲ +43.9%
Ns
Norský státní fond
Norges Bank
0.01%$129,539,464New position
KF
Ken Fisher
Fisher Investments
0%$10,233,363▼ -2.9%

Frequently asked questions

How much is Resmed Inc (RMD) stock?

Resmed Inc shares trade at $252.86, -0.08% over the last trading day. The price is delayed.

What is the market cap of Resmed Inc?

The market cap of Resmed Inc is about $35.6B and its price-to-earnings ratio (P/E) is 24.2.

Does Resmed Inc pay a dividend?

The dividend yield of Resmed Inc is 1.04% a year. The yield can change with the company's decisions.

How has Resmed Inc stock performed over the last year?

The Resmed Inc share price changed by -2.56% over 12 months and by -3.82% over 5 years.

Which big investors hold Resmed Inc?

According to the latest 13F filings, 10 of 87 tracked investors hold Resmed Inc, for example François Rochon, Cliff Asness, Ray Dalio.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms (Czech)Privacy (Czech)Cookies (Czech)

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

  • Cost of sales 39
  • Research 6.7
  • Operations and selling 20.6
  • Taxes and other 6.8
  • Net profit 26.9

Out of 100 USD of revenue, 26.9 USD is left as net profit.

Is it financially healthy?

Yes
Cash
1.5B USD
Debt
826M USD
Free CF
939M USD

It has more cash than debt.

Does it pay a dividend?

Pays
Yield
1.04%
Of earnings
23%

Over a year you receive roughly 1.04% of the price per share. The payout is manageable for the company. It has raised the dividend for 9 years in a row.

What do analysts expect?

Buy
Average target
251.52 USD
Vs price
−1%

17 analysts. Their opinion is not a recommendation by FinBoss.io.

Which big investors hold it?

10 of 87

Among the tracked investors, François Rochon, Cliff Asness, Ray Dalio and others hold the stock according to 13F filings.

Dividend per share by year (USD)

* the year has not ended yet. Source: Yahoo Finance.

Ratios

P/E
24.2×
Forward P/E
19.1×
P/B
5.5×
P/S
6.3×
PEG
1.47
EV/EBITDA
17.1×
Gross margin
61.6%
Operating margin
30.9%
Net margin
26.9%
ROE
24.3%
ROA
14.0%
Debt / equity
0.1×
Current ratio
3.1×
Revenue growth
8.6%
Earnings growth
2.4%
Beta
0.75
Dividend
1.04%
Payout ratio
23%